Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on February 16, 2017. The report addresses corporate governance changes effective immediately on the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Election of Directors: Daniel J. Starks was named to the Abbott Board of Directors, effective February 16, 2017.
- By-Law Amendment: The Board amended Article III, Section 2 of the By-Laws to increase the number of directors from eleven to twelve persons, effective February 16, 2017.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the official appointment of Daniel J. Starks to the Board of Directors.
- Confirm the updated Board size of twelve members as reflected in the amended By-Laws (Exhibit 3.1).
- Note that this filing contains no financial results or operational updates.